Compare · ATRC vs MDLN
ATRC vs MDLN
Side-by-side comparison of AtriCure Inc. (ATRC) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATRC and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $52.27B, about 29.5x ATRC ($1.77B).
- ATRC has been more active in the news (6 items in the past 4 weeks vs 4 for MDLN).
- MDLN has more recent analyst coverage (25 ratings vs 14 for ATRC).
- Company
- AtriCure Inc.
- Medline Inc.
- Price
- -
- -
- Market cap
- $1.77B
- $52.27B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2025
- News (4w)
- 6
- 4
- Recent ratings
- 14
- 25
AtriCure Inc.
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. The company also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used to treat symptomatic persistent and long-standing persistent atrial fibrillation patients; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, it sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; COBRA Fusion Surgical Ablation System; Fusion Magnetic Retriever System; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company markets and sells its products through independent distributors and direct sales personnel. AtriCure, Inc. was incorporated in 2000 and is headquartered in Mason, Ohio.
Latest ATRC
- President, CEO, & Director Carrel Michael H was granted 636 shares, increasing direct ownership by 0.08% to 779,134 units (SEC Form 4)
- Chief Scientific Officer Doraiswamy Vinayak was granted 636 shares, increasing direct ownership by 0.69% to 92,511 units (SEC Form 4)
- Chief Legal Officer Dahlquist Karl S. was granted 636 shares, increasing direct ownership by 0.66% to 96,689 units (SEC Form 4)
- Chief Operating Officer Seith Douglas J was granted 527 shares, increasing direct ownership by 0.23% to 229,867 units (SEC Form 4)
- Chief Technical Officer Privitera Salvatore was granted 636 shares, increasing direct ownership by 0.40% to 158,684 units (SEC Form 4)
- AtriCure to Announce Second Quarter 2026 Financial Results
- SEC Form SD filed by AtriCure Inc.
- AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
- Director Prange Karen sold $85,950 worth of shares (3,000 units at $28.65), decreasing direct ownership by 10% to 26,373 units (SEC Form 4)
- Director Prange Karen was granted 6,144 shares, increasing direct ownership by 26% to 29,373 units (SEC Form 4)
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Leadership Update
- Medline announces Prime Vendor agreement with Allina Health
- Securing new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
- Medline to report second quarter 2026 results on August 5, 2026
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Financial Officer Drazin Michael B covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)